James William Burns - 18 Jun 2026 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Reporting relationship: Chief Legal Officer
Issuer ticker: AGIO
Reported as of: 18 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jun 2026, 17:16:41 UTC
Prior SEC filing: 06 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ William Cook, as Attorney in Fact for James Burns

Key filing fact

James William Burns filed Form 4 for AGIOS PHARMACEUTICALS, INC. (AGIO) on 23 Jun 2026.

Key facts

This page summarizes James William Burns's Form 4 filing for AGIOS PHARMACEUTICALS, INC. (AGIO).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 23 Jun 2026, 17:16.

Change

Previous filing in this sequence was filed on 06 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001900772 Primary reporting owner

Burns James William

Relationship: Chief Legal Officer
Address: 88 SIDNEY STREET, CAMBRIDGE
Signature: /s/ William Cook, as Attorney in Fact for James Burns
Signature date: 23 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AGIO transaction Derivative

Performance share units

Options Exercise

Transaction value
Shares: -3,000
Change %: -25%
Price: $0.000000^*
Shares after: 9,000
Date: 18 Jun 2026
Ownership: Direct
Underlying class: Common stock
Underlying amount: 3,000
Exercise price
Footnotes: F1, F2

AGIO transaction Derivative

Restricted stock units

Award

Transaction value
Shares: +3,000
Change %
Price: $0.000000^*
Shares after: 3,000
Date: 18 Jun 2026
Ownership: Direct
Underlying class: Common stock
Underlying amount: 3,000
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each performance stock unit represents a contingent right to receive one share of the issuer's common stock.

Footnote F2

Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service.

Footnote F3

Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.